Activation of psoriasis in patients undergoing treatment with interferon;Aktivering af psoriasis hos patienter i interferon-β-behandling

Ugeskrift for Laeger

Volumn 167, Issue 32, 2005, Pages 2903-2904

  Navne, Johan Emdal ^a   Hedegaard, Ulla ^a   Bygum, Anette ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CASE REPORT; CHRONIC INFLAMMATION; DISEASE EXACERBATION; HUMAN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; PSORIASIS; SKIN INFLAMMATION; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; PSORIASIS;

EID: 23844559271     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986;1:1466-9.
2. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant Interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990;126:351.
3. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995;33:393-410.
4. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002;107:133-44.
5. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol 1997;27:553-8.